

Trust Headquarters
Russells Hall Hospital
Dudley
West Midlands
DY1 2HQ

Ref: FOI-072025-0001767

Date: 13.8.25

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000.

I have a freedom of information request regarding the treatment of certain types of cancer. Could you please answer the following questions.

Q1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- Atezolizumab (Tecentriq) - **3**
- Durvalumab (Imfinzi) - **2**
- Nivolumab (Opdivo) - **0**
- Pembrolizumab (Keytruda) - **3**
- Chemotherapy - **17**
- Radiotherapy - **Not at this Trust**
- Chemotherapy AND Radiotherapy - **Not at this Trust**
- Osimertinib - **11**

Q2. How many patients has your trust treated in the last 3 months with Pembrolizumab for stage II Melanoma? - **0**

Q3. How many patients has your Trust treated in total in the past 3 months for

- Stage 2 Non-Small Cell Lung Cancer - **17**
- Stage 3 Non-Small Cell Lung Cancer - **30**

Q4. How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- Atezolizumab - **3**
- Pembrolizumab monotherapy - **3**
- Pembrolizumab with chemotherapy - **4**
- Nivolumab - **0**
- Osimertinib - **9**

- Durvalumab - **2**
- Chemotherapy - **8**
- Radiotherapy - **Not at this Trust**
- Chemotherapy and Radiotherapy - **Not at this Trust**

Q5. How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months following surgery with:

- Chemotherapy - **15**
- Radiotherapy - **Not at this Trust**
- Chemotherapy + Radiotherapy - **Not at this Trust**

Q6. How many Stage 2-3 resectable non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- Durvalumab - **0**

Q1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- Atezolizumab (Tecentriq) - **3**
- Durvalumab (Imfinzi) - **2**
- Nivolumab (Opdivo) - **0**
- Pembrolizumab (Keytruda) - **3**
- Chemotherapy - **17**
- Radiotherapy - **Not at this Trust**
- Chemotherapy AND Radiotherapy - **Not at this Trust**
- Osimertinib - **11**

Q2. How many patients has your trust treated in the last 3 months with Pembrolizumab for stage II Melanoma? - **0**

Q3. How many patients has your Trust treated in total in the past 3 months for

- Stage 2 Non-Small Cell Lung Cancer - **17**
- Stage 3 Non-Small Cell Lung Cancer - **30**

Q4. How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- Atezolizumab - **3**
- Pembrolizumab monotherapy - **3**
- Pembrolizumab with chemotherapy - **4**
- Nivolumab - **0**
- Osimertinib - **9**
- Durvalumab - **2**
- Chemotherapy - **8**
- Radiotherapy - **Not at this Trust**
- Chemotherapy and Radiotherapy - **Not at this Trust**

Q5. How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months following surgery with:

- Chemotherapy - **15**
- Radiotherapy - **Not at this Trust**
- Chemotherapy + Radiotherapy - **Not at this Trust**

Q6. How many Stage 2-3 resectable non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- Durvalumab - **0**

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team
The Dudley Group NHS Foundation Trust